Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure

Key Takeaways

• Citi maintains Buy, $60 target for Olema.
• Stifel initiates Buy, $48 target, $3.1B sales model.
• COO/CFO Shane Kovacs departs, remains consultant.
• CEO Sean Bohen assumes interim CFO duties.
• Endocrine therapy market exceeds $20B, strong growth.

Summary

Citi reaffirmed its Buy rating on Olema Pharmaceuticals, setting a $60 price target, while Stifel initiated coverage with a Buy rating and a $48 target, modeling peak 2035 sales of $3.1 billion for the lead asset palazestrant. The bullish outlook follows the departure of COO/CFO Shane Kovacs, who will stay on as a consultant, with CEO Sean Bohen temporarily assuming CFO duties. Olema focuses on next‑generation oral therapies for women’s cancers, including the dual‑action candidate OP‑1250. Hedge‑fund holdings rose sharply in Q4 2025, underscoring market interest.

Pulse Analysis

Olema Pharmaceuticals is carving a niche in women’s oncology with its oral candidate OP‑1250, a novel combination of a complete estrogen receptor antagonist and a selective degrader. This dual mechanism aims to deliver deeper, more durable responses than existing hormone therapies, addressing an unmet need in breast and ovarian cancer treatment. By targeting a specific patient subset, Olema hopes to differentiate its pipeline and capture a share of the expanding endocrine‑therapy market, which analysts estimate could surpass $20 billion globally.

The recent analyst upgrades from Citi and Stifel underscore a growing conviction in Olema’s commercial prospects. Citi’s $60 price target reflects confidence in the company’s long‑term value creation, while Stifel’s $48 target is anchored in a conservative sales projection of $3.1 billion for palazestrant by 2035. Both firms highlighted robust hedge‑fund momentum, with 28 new holders added in the last quarter, suggesting that institutional investors are betting on the company’s ability to translate its scientific advances into revenue. Notably, the bullish stance persists despite the abrupt COO/CFO departure, indicating that the leadership change is viewed as a manageable transition rather than a fundamental risk.

From an industry perspective, Olema operates in a competitive landscape where large pharma players are also pursuing next‑generation endocrine therapies. Success will hinge on clinical trial outcomes, regulatory approvals, and the ability to scale manufacturing. If Olema can demonstrate superior efficacy and safety, it could secure partnerships or licensing deals that accelerate market entry. However, investors should monitor execution milestones and the timeline for appointing a permanent CFO, as financial stewardship will be critical to sustaining growth and delivering on the lofty sales forecasts.